Interaction between midazolam and clarithromycin in the elderly

British Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2008, Pages 98-109

  Quinney, Sara K ^a   Haehner, Barbara D ^a   Rhoades, Melissa B ^a   Lin, Zhen ^a   Gorski, J Christopher ^a,b   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Formulation Development Services   (India)

Author keywords

Clarithromycin; CYP3A; Cytochrome P450; Elderly; Midazolam

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 3A; LIVER PROTEIN; MIDAZOLAM; NITROGEN 15;

AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INTESTINE; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; MIDAZOLAM; REGRESSION ANALYSIS;

EID: 37249022370     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02970.x     Document Type: Article

References (39)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994 270 : 414 23.
2. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome p450 'pie'. Drug Metab Dispos 2006 34 : 880 6.
3. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383 91.
4. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, Roger M. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005 33 : 884 7.
5. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005 37 : 178 81.
6. Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rerolle JP, Marquet P. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 80 : 51 60.
7. Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005 77 : 178 88.
8. Gorski J, Wang Z, Hall S. Duration of CYP3A Inhibition by Clarithromycin. Presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 2002.
9. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr., Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998 64 : 133 43.
10. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, O'Connell PJ. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997 43 : 194 6.
11. Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994 58 : 725 7.
12. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant 1994 13 : 343 5.
13. Geronimo-Pardo M, Cuartero-del-Pozo AB, Jimenez-Vizuete JM, Cortinas-Saez M, Peyro-Garcia R. Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother 2005 39 : 538 42.
14. Malone DC, Hutchins DS, Haupert H, Hansten P, Duncan B, Van Bergen RC, Solomon SL, Lipton RB. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005 62 : 1983 91.
15. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992 44 : 275 83.
16. Hunt CM, Westerkam WR, Stave GM, Wilson JA. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992 64 : 189 99.
17. Chu SY, Wilson DS, Guay DR, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992 32 : 1045 9.
18. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994 47 : 1643 53.
19. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984 61 : 27 35.
20. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997 51 : 741 54.
21. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989 9 : 297 301.
22. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Baltimore : Williams & Wilkins 1995.
23. Gorski JC, Wang Z, Haehner-Daniels BD, Wrighton SA, Hall SD. The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther 2000 68 : 412 7.
24. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003 74 : 275 87.
25. FDA. Guideline for industry studies in support of special populations: geriatrics. In : ICH Steering Committee, ed. Washington, DC : Food and Drug Administration 1994.
26. Loi CM, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997 280 : 627 37.
27. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999 16 : 408 14.
28. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994 271 : 557 66.
29. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994 271 : 549 56.
30. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996 59 : 491 502.
31. Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 1998 63 : 552 60.
32. Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schuttler J. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999 65 : 630 9.
33. Klotz U. [Clinical pharmacology of midazolam]. Anaesthesiol Reanim 1989 14 : 347 54.
34. Kashuba AD, Bertino JS Jr., Rocci ML Jr., Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998 64 : 269 77.
35. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992 36 : 1147 50.
36. Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, Sonders RC. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 1992 36 : 2447 53.
37. Chu S, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993 33 : 719 26.
38. Edgar B, Hoffmann KJ, Lundborg P, Regardh CG, Ronn O, Weidolf L. Absorption, distribution and elimination of felodipine in man. Drugs 1985 29 (Suppl. 2 9 15.
39. Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001 71 : 1303 7.